Research programme: serotonin reuptake inhibitors/serotonin 1A receptor antagonists - Pfizer

Drug Profile

Research programme: serotonin reuptake inhibitors/serotonin 1A receptor antagonists - Pfizer

Alternative Names: SSA-426; SSRI/5HT1A receptor antagonist - Wyeth; WAY-163426; WAY-211612; WAY-253752; WAY-426

Latest Information Update: 20 Oct 2009

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Chromans; Quinolines
  • Mechanism of Action Serotonin 1A receptor antagonists; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Anxiety disorders; Major depressive disorder; Obsessive-compulsive disorders

Most Recent Events

  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 06 Aug 2009 Preclinical development is ongoing in USA
  • 17 Apr 2007 Data presented at the 233rd American Chemical Society National Meeting (ACS-2007) added to the Affective Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top